Iantrek, Inc. announced it has secured $42 million in a recent Series C financing round to support the future launch of its latest bio-interventional product for glaucoma: the AlloFlo Uveo.
First up: Iantrek.
The venture-funded medical technology company specializes in micro- and bio-interventional eye surgery solutions for chronic ocular diseases.
Specifically: Iantrek’s focus lies in a new bio-interventional surgical category based on a combination of natural allogeneic biotissues and high-precision micro-interventional technology.
- As for its portfolio: This encompasses uveoscleral and trabecular minimally-invasive glaucoma surgery (MIGS) devices in varying stages of product development—including commercially available.
- See here for a look at all five technologies in the proprietary Allo platform.
… and in recent news?
Within the last 6 months or so, the company has:
- Named a new CEO (Adam Szaronos, Trukera Medical’s former president and CEO)
- Released favorable 2-year data on one of its technologies: the CycloPen System
- Notably: Not the device for which this recent fundraising supported
Plus: The American Academy of Ophthalmology (AAO) has also endorsed a reimbursement for cyclodialysis with scleral reinforcement.
Now to this financing.
As we mentioned earlier, this Series C financing round clocked in $42 million.
The investment was led by U.S. Venture Partners and joined by aMoon Fund as well as the company’s pre-existing investors:
- Visionary Ventures
- Sectoral Asset Management
- Radius Special Situations Fund
- Civilization Ventures
Noted. Next up: this device.
The AlloFlo Uveo is one of two glaucoma devices Iantrek shared plans for earlier this year to begin a “controlled release stage” to the U.S. market—followed by a “full commercial launch.”
- That other device: C-Rex (for canal outflow enhancement in glaucoma surgery), reported to be the only FDA-registered MIGS tech to perform excisional circumferential trabeculorhexis and dual wall canal intervention.
But more about the AlloFlo Uveo: Referred to as a “first-of-its-kind surgical solution targeting the uveoscleral pathway,” the device is designed for high precision ab-interno homologous structural reinforcement.
Tell me more.
Quite simply: The system offers ophthalmic surgeons another route to drain fluids from the eye via a porous, biologic material that adheres to and reinforces specific channels around the cornea’s edge.
As Iantrek previously noted, the AlloFlo Uveo “offers a hardware-free, naturally-derived bio-tissue solution for patients suffering from glaucoma.”
Has any clinical data been published on it?
Quite recently, actually. In fact, new peer-reviewed research published in Ophthalmology Science reported positive findings regarding the long-term efficacy and safety of the AlloFlo Uveo.
Specifically: Using the device to perform bio-reinforced cyclodialysis combined with phacoemulsification (cataract surgery).
- The findings, per the authors: A significant and sustained reduction in IOP (with few ocular adverse events and complications) was demonstrated when using the Allo-Flo Uveo combined with cataract surgery for patients with primary open-angle glaucoma (POAG).
- The mean IOP reduction (after 2 years): 34%
- >60% decrease in IOP-lowering medication use
Nice! Any other promising outcomes?
Indeed. In fact, the AlloFlo Uveo marked a milestone achievement just a few months ago: surpassing 2,000 procedures performed by early clinical adopter ophthalmic surgeons across the United States.
Since then: The number of procedures performed has risen to an estimated 3,000.
Lastly, what do we know about this anticipated launch?
As Iantrek previously shared in May 2025, the company plans to launch the device to the U.S. commercial market during the AAO’s 2025 annual meeting in October in Orlando, Florida.
As always, stay tuned for more details!